Literature DB >> 8124818

Kinetic properties of 99mTc-Q12 in canine myocardium.

M C Gerson1, R W Millard, N J Roszell, A J McGoron, M Gabel, L C Washburn, D Biniakiewicz, D Blankenship, W H Mallin, R C Elder.   

Abstract

BACKGROUND: 99mTc-Q12 is a new Tc(III) perfusion imaging agent that permits prompt myocardial visualization in humans. We postulated that 99mTc-Q12 myocardial activity is related to actual myocardial blood flow during conditions of myocardial ischemia and pharmacological coronary artery vasodilation and that 99mTc-Q12 shows little or no myocardial redistribution as long as 4 hours after intravenous injection. METHODS AND
RESULTS: In seven anesthetized, open chest dogs, the left circumflex coronary artery was occluded, and dipyridamole (0.32 or 0.56 mg/kg) was infused into the right atrium, followed by 10 mCi of 99mTc-Q12. Myocardial blood flow was measured by radiolabeled microspheres. The animals were euthanized, and a total of 315 myocardial samples were assayed in a well counter for 99mTc activity. One week later, radiolabeled microsphere activity was determined, and myocardial blood flow was calculated. 99mTc activity (y) was related to myocardial blood flow (x) from 0 to 2 mL.g-1 x min-1 by the relation y = 0.64x + 0.35 (r = .88, P = .0001). In 14 additional anesthetized, open chest dogs, an occluder was placed around the left circumflex coronary artery, and an ischemic level of circumflex blood flow was maintained constant over 4 hours as measured by an ultrasonic flowmeter. Dipyridamole (0.56 mg/kg) was infused intravenously beginning 15 minutes after coronary occlusion and then followed by 10 mCi of 99mTc-Q12. Gamma camera images, hemodynamics, microsphere blood flow, and endocardial biopsies (latter in six dogs) were performed at 30, 60, 120, and 240 minutes after 99mTc-Q12 injection. Myocardial blood flow in the distribution of the left anterior descending artery decreased by 29.6% from 30 to 240 minutes (P < .05), whereas left circumflex blood flow increased by 40.4% from 30 to 120 minutes (P < .05) as the dipyridamole hemodynamic effects dissipated. Nevertheless, the ratio of myocardial perfusion defect zone counts to normal myocardial zone counts remained constant over 4 hours, as did the technetium counts from the needle biopsy endocardial samples.
CONCLUSIONS: Over a limited range of myocardial blood flows from 0 to approximately 2 mL.g-1 x min-1, 99mTc-Q12 myocardial activity is related to actual myocardial flow at the time of tracer injection. 99mTc-Q12 shows no evidence of myocardial redistribution.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8124818     DOI: 10.1161/01.cir.89.3.1291

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  8 in total

1.  Proceedings of the 4th Invitational Wintergreen Conference. Wintergreen, Virginia, USA. July 12-14, 1998. Abstracts.

Authors: 
Journal:  J Nucl Cardiol       Date:  1999 Jan-Feb       Impact factor: 5.952

2.  Furifosmin: the road to the final four.

Authors:  A S Iskandrian
Journal:  J Nucl Cardiol       Date:  1996 Jul-Aug       Impact factor: 5.952

Review 3.  Experimental evaluation of radiotracers: role of intact biological models.

Authors:  A J Sinusas
Journal:  J Nucl Cardiol       Date:  1998 Mar-Apr       Impact factor: 5.952

4.  Technetium 99m furifosmin regional myocardial uptake in patients with previous myocardial infarction: relation to thallium-201 activity and left ventricular function.

Authors:  A Cuocolo; G Rubini; W Acampa; E Nicolai; L Florimonte; G DiGiovine; A D'Addabbo; M Salvatore
Journal:  J Nucl Cardiol       Date:  2000 May-Jun       Impact factor: 5.952

5.  Biokinetics and dosimetry analysis in healthy volunteers for a two-injection (rest-stress) protocol of the myocardial perfusion imaging agent technetium 99m-labeled Q3.

Authors:  R C Rohe; S R Thomas; M G Stabin; E A Deutsch; M C Gerson; D D Cummings; H R Maxon
Journal:  J Nucl Cardiol       Date:  1995 Sep-Oct       Impact factor: 5.952

6.  Comparison of technetium 99m Q12 and thallium 201 for detection of angiographically documented coronary artery disease in humans.

Authors:  M C Gerson; J Lukes; E Deutsch; D Biniakiewicz; R C Rohe; L C Washburn; C Fortman; R A Walsh
Journal:  J Nucl Cardiol       Date:  1994 Nov-Dec       Impact factor: 5.952

7.  Comparison of imaging properties of technetium 99m Q12 and technetium 99m Q3 in humans.

Authors:  M C Gerson; J Lukes; E Deutsch; D Biniakiewicz; L C Washburn; R A Walsh
Journal:  J Nucl Cardiol       Date:  1995 May-Jun       Impact factor: 5.952

8.  Diagnostic utility of tomographic myocardial perfusion imaging with technetium 99m furifosmin (Q12) compared with thallium 201: results of a phase III multicenter trial.

Authors:  R C Hendel; M S Verani; D D Miller; F J Wackers; M McMahon; M D Cerqueira; E H Botvinick; L Kvols; M C Gerson
Journal:  J Nucl Cardiol       Date:  1996 Jul-Aug       Impact factor: 5.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.